EURASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES
Innovative Academy Research Support Center
IF = 9.2 www.in-academy.uz/index.php/ejmns

DISCUSSION OF MEASURES TO IMPROVE THE DIAGNOSIS OF BACTERIAL DISEASES

Dilafruz Sh. Gulmurotova[1]
Charos X. Baratova[2]
[1]Assistant at the Department of Microbiology, virology and immunology of Tashkent State Medical University, Tashkent, Uzbekistan, E-mail: dilafruzgulmurotova82@gmail.com
[2]Student of Tashkent State Medical University, 1st Faculty of General Medicine, Group 217A, Tashkent, Uzbekistan, E-mail: cbaratova469@gmail.com
https://doi.org/10.5281/zenodo.17589049

ARTICLE INFO

Received: 06th November 2025
Accepted: 11th November 2025
Online: 12th November 2025

KEYWORDS

Quick diagnostics, Critical care, sepsis, bloodstream infection, antibiotic resistance, antimicrobial susceptibility testing.

ABSTRACT

This article's goal is to examine the performance, advantages, and disadvantages of the new and existing microbiological methods that aid in the quick detection of bacterial infections in critically sick patients, as well as the data that is currently available to assess their clinical significance. Significant morbidity and death are caused by bacterial infections and sepsis in patients hospitalized to the critical care unit, and the growing worldwide burden of antibiotic resistance makes managing these conditions even more difficult. In this context, novel diagnostic techniques that can surpass the accuracy and turnaround time constraints of conventional microbiology are greatly needed. The optimization of current culture-based techniques, rapid antigen detection, nucleic acid detection (including multiplex PCR assays and microarrays), sepsis biomarkers, new techniques for pathogen detection (like T2 magnetic resonance) and susceptibility testing (like morphokinetic cellular analysis), and the use of direct metagenomics on clinical samples are some of the general topics we cover. New "omics" technologies that measure the host response may also help identify non-infectious inflammatory states and help with early infection identification. Evidence regarding the practical effects of these assays on patient care is still lacking, despite the field's potential. Studies that are now available have generally found that whether or not fast diagnostic techniques are incorporated into active antimicrobial stewardship programs has a significant impact on how well they work. Large-scale, carefully planned studies are needed to

overcome the difficult task of evaluating the effects of these new diagnostic techniques on patient-centered clinical outcomes.

Introduction. Both adults and children hospitalized to the intensive care unit (ICU) frequently have bacterial infections. Of 3147 patients in a cohort of 198 intensive care units across 24 European nations, 37.4% had sepsis, and 24.7% had sepsis when they were admitted. These patients' infections are linked to high rates of morbidity, mortality, and expense. Antibiotic use is also high due to infection concerns; in a global point-prevalence survey, 70% of all intensive care unit patients were receiving at least one antibiotic on any given day. Clinical care of bacterial infections requires the ability to quickly and precisely identify the culprit causing the infection. Furthermore, fast antimicrobial susceptibility testing (AST) is becoming more and more crucial to guiding therapy as the global burden of antibiotic resistance increases. We urgently need diagnostic techniques that can assist rule out infection and identify non-infectious inflammatory states for which antibiotics are not necessary, especially in light of the need to reduce the overuse of antibiotics. The majority of the diagnostic techniques used today to identify bacteremia in patients who present with sepsis rely on the culture of blood microorganisms [1-6]. Nevertheless, in addition to being comparatively slow and time-consuming, culture-based systems have several pre-analytical limitations that can impact performance, including insufficient blood volume collection, previous exposure to antibiotics, and delays in laboratory processing or transportation, particularly if laboratory facilities are located off-site. Furthermore, it may take a few days to conduct susceptibility testing and conclusive identification of an organism, even after it has been grown. A common issue that can arise during blood culture (BC) collection is contamination, which can lead to improper antibiotic administration, skew clinical diagnosis, and expose patients to needless toxicities. Numerous infections are also picky eaters, making it difficult to cultivate them in conventional automated systems. There are several new or developing technologies that have the potential to completely change the way microbiological diagnoses are carried out in the near future, even though clinical microbiology labs have historically relied on methods that haven't changed much over the years [7-10]. Ten years ago, mass spectrometry techniques were not commonplace in laboratories. However, with gradual improvements in turn-around times (TATs), accuracy, and cost savings, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF) has quickly supplanted traditional bacterial identification techniques in many labs. Reviewing the state of the art as well as new and developing technologies that could enhance our ability to quickly and accurately diagnose patients with sepsis and serious bacterial infections microbiologically is the goal of this essay. The diagnosis of many infectious disorders, such as sepsis, pneumonia, and culture-negative endocarditis, is still challenging, despite the fact that the application of contemporary molecular and biochemical technology has enhanced the performance of many diagnostic modalities. To enhance the detection of infectious diseases, new point-of-care (POC) diagnostics are required, particularly in developing nations with

inadequate infrastructure and undertrained healthcare workers. POC tests are intended to be utilized directly on-site and to yield quick results, allowing for better clinical outcomes and prompt clinical decision-making [11-15]. According to the World Health Organization (WHO), the perfect proof of concept test would meet the ASSURED requirements, which include being inexpensive, sensitive, specific, easy to use, quick and reliable, equipment-free, and deliverable to end users. As a result, the tests can be used anywhere in the globe without the need for complex lab equipment, and even operators who lack a thorough understanding of the test concept can simply interpret the results. The technologies currently in use for bacterial illness detection and antibiotic resistance trends are highlighted in this article (Table 1 provides a comparative overview). Results that highlight the necessity of contemporary diagnostic tools for detecting newly developing bacterial illnesses are provided [16,17,18].

The main purpose of the presented manuscript is to discuss measures to improve the diagnosis of bacteriological diseases based on reputable scientific research.

Traditional Microbiological Methods. The gold standard for detecting bacterial infections for almost a century was to grow the pathogens in cell culture and then evaluate them using biochemical techniques meant to identify different species and strains of microorganisms. Cultivating bacteria is economical and typically yields a diagnosis with high specificity. However, the turnaround periods for this method are lengthy (usually ranging from 24 to 72 hours for cultivation and another 18 to 24 hours for the isolates' biochemical characterisation). These techniques, however, frequently lack sensitivity and produce errors related to collection conditions and specialized growth media requirements; this is especially restrictive when one must take infection with one or more picky microorganisms into account. The time required to identify a particular bacterial species is shortened from hours to a few minutes by using contemporary mass spectrometry techniques, such as matrix-assisted laser desorption ionization time of flight (MALDI-TOF). However, bacterial culture is still a prerequisite for using MALDI-TOF. The inability to identify non-cultivable pathogen species is one of the main disadvantages of routine bacterial culture. Therefore, further diagnostic techniques are required [12-20].

How Should New Rapid Diagnostics' Clinical Utility Be Assessed? Although it is a crucial element, a test's increased utility cannot be demonstrated just by a decrease in turn-around time (TAT) in either identification or susceptibility data. The sensitivity, specificity, type of result obtained, and confidence of the appropriate clinician acting upon the finding are additional criteria. TATs and AMS results are perhaps only one aspect of a comprehensive evaluation of the significance and worth of quick diagnostic microbiological methods. To assess several important clinical and procedural outcomes, including mortality, acute renal injury, duration of stay, and readmission, we require controlled trials or interrupted time series studies conducted over long periods of time [1-5]. A thorough cost-effectiveness analysis that evaluates not only hospital admission expenses but also the value of quality-adjusted life years (QALY) saved, the costs of laboratory implementation of RDT programs, and adjunct AMS programs would be excellent.

Although there are several quasi-studies that have assessed AMS outcomes, many of which have included a variety of clinical or process outcomes, there is a dearth of high-quality evidence in this area. The Infectious Diseases Society of America (IDSA) guidelines reflect the most consistent, albeit not universal, finding that rapid technologies by themselves do not translate into better AMS outcomes, let alone improved clinical outcomes, without also integrating customized AMS support strategies. Extended service hours, alerting a member of the AMS team to crucial results, and other activities that enhance clinical engagement are examples of focused AMS techniques that have been tested to promote the adoption of RDT. Improvements in de-escalation and appropriate antimicrobial usage are the most consistent results when these tactics are combined with RDTs; cost savings is the least represented. Impact on clinical outcomes has varied greatly in studies measuring death, re-admission, and duration of stay [7-12].



Figure 1 shows the average amount of time needed for methods currently used to diagnose bacterial infections [6].

Although the causes have not been thoroughly investigated, other stewardship research suggests that they have to do with prescribing practices, a lack of familiarity, and a lack of expertise or expert knowledge regarding the actionability of RDT results. The institution's local antibiograms, patient complexity and strength of present AMS, and relationships with infectious disease and microbiology teams will all affect how well the benefits of introducing such services are demonstrated. The expense of molecular technologies may be prohibitive for low- and middle-income countries with large frequencies of community multidrug-resistant organisms, but quick phenotypic testing or portable, low-footprint optical sensor techniques may be crucial [1,3,4,5].

POC Testing of Antimicrobial Resistance: Innovative and Fast Testing Methods. Since antimicrobial resistance and susceptibility test findings are typically unavailable at the time of therapy initiation, antibiotic therapy is first empirical. Susceptibility profiles should ideally be accessible as soon as feasible, particularly while caring for patients who are in critical condition. In order to provide MIC values in a multiplex mode for a large cohort of available antibiotics (the most promising and currently available approaches are illustrated), POC antimicrobial resistance tests must be affordable and primarily automated. They must also be able to handle small volumes of material to be tested. All of the previously stated approaches satisfy some of these requirements, but none of them are successful when all of these factors are taken into account. Biosensors may shed light on different resistance mechanisms and use modest test quantities. As a result, this technology may offer the possibility of combining sensitive and quick detection of genes linked to resistance with the potential to be employed alone or in conjunction with a POC test [3-9]. Electrochemical technologies, like EIS, can facilitate the direct, amplification-free, and label-free detection of blaNDM plasmid genes, including the New Delhi metallo-β-lactamase, by hybridization, according to Huang and colleagues. To make it easier to find the resistance gene mecA, additional electrochemical-based tests have been created. These tests do not identify antibiotic susceptibility, despite the fact that they offer quick identification of important resistance-associated genes. While numerous efforts have been made to construct POC-AST devices, the majority of these approaches generally satisfy some of the previously listed requirements; nonetheless, none of these devices are currently completely suitable. To create POC tests that are clinically useful, a variety of technologies as well as fresh concepts and tactics will be required [14-20].

Diagnostics at the Point of Care. The majority of the techniques covered so far necessitate a functional laboratory and at least some scientific knowledge and training. Higher complexity tests are often saved for labs with the necessary equipment, and only assays that are easy to use and have a minimal chance of producing inaccurate findings are typically authorized for POCT. However, there is a delay and a certain amount of separation between the patient and the treating physicians when utilizing a laboratory-based test. This can cause significant delays for crucial tests like BCs or molecular diagnostics in geographically dispersed nations with isolated areas. As with the majority of other jurisdictions, POCT providers in Australia are required to follow specific guidelines that outline proper governance, test integrity maintenance, pre-, analytical,

and post-analytical error minimization, appropriate training, and competency assessment. All of these procedures are integrated into a strong quality management system. Over time, these procedures have changed to guarantee that physicians can trust the test results they obtain. For the precise diagnosis of bloodstream infections and the majority of other serious illnesses, there is currently no POCT available [11-15]. There is some promise for the future thanks to technical advancements like microfluidic devices that can combine signal creation and sampling handling in a POCT context, maybe with the use of testing platforms like nucleic acid analysis or "on-chip" immunoassays. All of the essential procedures of molecular detection, including cell lysis and extraction, nucleic acid purification, amplification, and reaction product detection, can theoretically be included in such technology. Multiplexing to facilitate high-throughput testing within a single portable device may also be made possible by such miniaturization. Although the design, construction materials, and sensing technologies of such devices are the subject of extensive pre-clinical study, no commercial products are yet prepared for clinical review [6-10].

Discussion. Effective treatment of infections, which are becoming a bigger issue in intensive care medicine, depends on the quick and accurate identification and characterisation of microorganisms and patterns of antibiotic resistance. In terms of turnaround times and general efficacy, the current state of affairs is still far from ideal. The patient prognosis is worse and the development of resistance mutants is further accelerated by the application of an inadequate antimicrobial agent or the needless use of broad-spectrum antibiotics. Here, we present an overview that takes into account the underlying molecular principles and technologies as well as an assessment and comparison of the current methods for diagnosing bacterial infections. Particular focus is given to recent findings that could result in major advancements in the diagnosis and point-of-care detection of multi-resistant bacteria, as well as fresh approaches that could steer antibiotic treatment. Significant advancements have been made in the creation of technologies for infectious illness detection in recent years. The field of infectious disease diagnostics has undergone a revolution thanks to culture-independent techniques like NATs and NGS-based tactics, which offer quick results and make it easier to identify pathogens that cannot be grown. There are still issues that need to be resolved in spite of these remarkable technological advancements. Only a small number of diseases now have approved molecular testing accessible, and these diagnostics are also significantly underutilized [3-12]. Slow response times, subpar test results, restricted access to testing materials, and expensive costs are some of these tests' main drawbacks. The perfect diagnostic test would be affordable, precise, simple to use with universally accessible equipment and resources, yield results quickly without requiring prior knowledge of the likely causal agents, and direct the right antimicrobial therapeutic alternatives. LFIAs, biosensors, and paper-based NAT devices are among the POC tests that show a great deal of promise in meeting all of these needs. The tests that are currently available, meanwhile, are far from perfect in terms of these detection tactics. Antibiotic-resistant infections will become more common and complicated in the upcoming years, which will present a greater challenge to healthcare systems around the globe. Culture-based techniques are

still widely used today for testing for antibiotic susceptibility as well as phenotypic characterisation. However, in order to provide appropriate isolation and treatment strategies for infected individuals, one will need to receive results immediately, therefore faster approaches will be required, especially those aimed at identifying microbial antibiotic resistance. By reducing the use of poor and partially effective antimicrobial medicines and lowering the chance of drug-resistant pathogens emerging, faster testing would improve patient outcomes. In conclusion, there is still a significant need for novel diagnostic approaches and alternatives to be used to the identification of pathogens and the description of bacterial illnesses. When used to the development of new infectious disease diagnostics, emerging methods such as host-based diagnostics, synthetic biology (e.g., phage-based diagnostics, CRISPR and Cas systems), and those based on artificial intelligence and machine learning have the potential to expand our knowledge and capacities [13-17].

Conclusions. There is currently little data regarding the practical effects of these assays on patient care, despite the field's promise. The effectiveness of fast diagnostic techniques is largely dependent on whether or not they are incorporated into active antimicrobial stewardship programs, according to a general conclusion of the research that are currently available. The evaluation of the effects of these new diagnostic techniques on patient-centered clinical outcomes is a difficult task that requires extensive and carefully planned research.

Numerous new microbiological techniques are probably going to improve our ability to quickly and precisely identify germs in patients who are in severe condition. To clarify their function in enhancing the treatment of severe infections, however, carefully planned research evaluating important clinical outcomes is required.

To summarize, new diagnostic alternatives and diagnostic procedures are still needed in significant quantities for the identification of pathogens and the description of bacterial diseases. The development of new infectious disease diagnostics could benefit from the application of emerging approaches such as host-based diagnostics, synthetic biology (e.g., phage-based diagnostics, CRISPR and Cas systems), and those based on artificial intelligence and machine learning.

References:

1. Peri AM, Stewart A, Hume A, Irwin A, Harris PNA. New Microbiological Techniques for the Diagnosis of Bacterial Infections and Sepsis in ICU Including Point of Care. Curr Infect Dis Rep. 2021;23(8):12. doi: 10.1007/s11908-021-00755-0.
2. Rodriguez-Sanchez B, Cercenado E, Coste AT, Greub G. Review of the impact of MALDI-TOF MS in public health and hospital hygiene, 2018. Euro Surveill. 2019;24(4):1800193. doi: 10.2807/1560-7917.ES.2019.24.4.1800193.
3. Chung Y, Kim IH, Han M, Kim HS, Kim HS, Song W, Kim JS. A comparative evaluation of BACT/ALERT FA PLUS and FN PLUS blood culture bottles and BD BACTEC Plus Aerobic and Anaerobic blood culture bottles for antimicrobial neutralization. Eur J Clin Microbiol Infect Dis. 2019;38(12):2229–2233. doi: 10.1007/s10096-019-03663-3.

4. Chen IH, Nicolau DP, Kuti JL. Effect of clinically meaningful antibiotic concentrations on recovery of Escherichia coli and Klebsiella pneumoniae isolates from anaerobic blood culture bottles with and without antibiotic binding resins. J Clin Microbiol. 2019;57(12).
5. Chen IH, Nicolau DP, Kuti JL. Recovery of Gram-negative bacteria from aerobic blood culture bottles containing antibiotic binding resins after exposure to beta-lactam and fluoroquinolone concentrations. J Clin Microbiol. 2019;57(10).
6. Rentschler S, Kaiser L, Deigner H-P. Emerging Options for the Diagnosis of Bacterial Infections and the Characterization of Antimicrobial Resistance. International Journal of Molecular Sciences. 2021; 22(1):456. https://doi.org/10.3390/ijms22010456
7. Srivastava, S.; Singh, P.K.; Vatsalya, V.; Karch, R.C. Developments in the diagnostic techniques of infectious diseases: Rural and urban prospective. Adv. Infect. Dis. 2018, 8, 121–138.
8. Tenover, F.C. The role for rapid molecular diagnostic tests for infectious diseases in precision medicine. Expert Rev. Precis. Med. Drug Dev. 2018, 3.
9. Miao, Q.; Ma, Y.; Wang, Q.; Pan, J.; Zhang, Y.; Jin, W.; Yao, Y.; Su, Y.; Huang, Y.; Wang, M.; et al. Microbiological diagnostic performance of metagenomic next-generation sequencing when applied to clinical practice. Clin. Infect. Dis. 2018, 67, 231–240.
10. Dave, V.P.; Anh, T.; Pernestig, N.A.; Tilevik, D.; Kant, K.; Nguyen, T.; Wolff, A.; Duong, D. MicroRNA amplification and detection technologies: Opportunities and challenges for point of care diagnostics. Lab. Investig. 2019, 452–469.
11. Sun, A.C.; Hall, D.A. Point-of-Care Smartphone-based Electrochemical Biosensing. Electroanalysis 2019, 2–16.
12. Young, B.A.; Hanson, K.E.; Gomez, C.A.; Hanson, K.E. Molecular diagnostic advances in transplant infectious diseases. Curr. Infect. Dis. Rep. 2019, 21, 52.
13. Boers, S.A.; Jansen, R.; Hays, J.P. Understanding and overcoming the pitfalls and biases of next-generation sequencing (NGS) methods for use in the routine clinical microbiological diagnostic laboratory. Eur. J. Clin. Microbiol. Infect. Dis. 2019, 38, 1059–1070.
14. Castillo, D.J.; Rifkin, R.F.; Cowan, D.A.; Potgieter, M. The healthy human blood microbiome: Fact or fiction? Front. Cell. Infect. Microbiol. 2019, 9, 148.
15. Taxt, A.M.; Avershina, E.; Frye, S.A.; Naseer, U.; Ahmad, R. Rapid identification of pathogens, antibiotic resistance genes and plasmids in blood cultures by nanopore sequencing. Sci. Rep. 2020, 10, 7622.
16. Roux-Dalvai, F.; Gotti, C.; Leclercq, M.; Hélie, M.C.; Boissinot, M.; Arrey, T.N.; Dauly, C.; Fournier, F.; Kelly, I.; Marcoux, J.; et al. Fast and accurate bacterial species identification in urine specimens using LC-MS/MS mass spectrometry and machine learning. Mol. Cell. Proteomics 2019, 18, 2492–2505.
17. Cesewski, E.; Johnson, B.N. Electrochemical biosensors for pathogen detection. Biosens. Bioelectron. 2020, 159, 112214.
18. Pirzada, M.; Altintas, Z. Recent Progress in Optical Sensors for Biomedical Diagnostics. Micromachines 2020, 11, 356.
19. Jiang, X.; Qavi, A.J.; Huang, S.H.; Yang, L. Whispering-Gallery Sensors. Matter 2020, 3, 371–392.

20. Minopoli, A.; Ventura, B.D.; Lenyk, B.; Offenhäusser, A.; Mayer, D.; Velotta, R.; Gentile, F.; Tanner, J.A. Ultrasensitive antibody-aptamer plasmonic biosensor for malaria biomarker detection in whole blood. Nat. Commun. 2020, 1–10.